[Retracted] Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia

Table 6

JC-1 results of SUP-B15 and NCI-BL 2171 cells.

Treatment group	Live cell (%)		Apoptotic cell (%)		Apoptotic fold change (to control)
	SUP-B15	NCI-BL 2171	SUP-B15	NCI-BL 2171	SUP-B15	NCI-BL 2171
Control	92.30	74.10	7.60	20.90	1.00	1.00
IC50 dose of prednisolone	0.30	76.30	99.70	17.60	13.10	0.80
Anti-miR-146a	79.20	68.70	20.60	24.80	2.70	1.20
Anti-miR-146a & IC50 dose of prednisolone	5.40	47.10	94.50	43.40	12.40	2.10
Anti-miR-155	75.40	64.20	24.30	29.40	3.20	1.40
Anti-miR-155 & IC50 dose of prednisolone	16.20	49.80	83.80	40.10	11.00	1.90
Anti-miR-181a	86.20	73.10	13.70	21.30	1.80	1.00
Anti-miR-181a & IC50 dose of prednisolone	15.00	58.20	83.30	33.20	11.00	1.60
Anti-let-7e	80.00	69.50	19.20	23.10	2.50	1.10
Anti-let-7e & IC50 dose of prednisolone	16.00	59.70	84.00	31.70	11.10	1.50
Anti-miR-146a + anti-miR-155 + anti-miR-181a + anti-let-7e combination	79.90	72.50	19.80	20.90	2.60	1.00
Anti-miR-146a + anti-miR-155 + anti-miR-181a + anti-let-7e combination & IC50 dose of prednisolone	3.90	59.60	96.10	30.80	12.60	1.50

Fisher’s exact test, <0.01 and <0.001.